These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 23474009)

  • 61. Glomerulonephritis, renal carcinoma, and solvent exposure: bias from choice of referents.
    Ravnskov U
    Br J Ind Med; 1990 Nov; 47(11):791-2. PubMed ID: 2245195
    [No Abstract]   [Full Text] [Related]  

  • 62. Pancytopenia and acute glomerulonephritis in an adolescent: Answers.
    Leventoğlu E; Büyükkaragöz B; Kaya Z; Fidan K; Söylemezoğlu O; Bakkaloğlu SA
    Pediatr Nephrol; 2021 Dec; 36(12):4023-4026. PubMed ID: 34086136
    [No Abstract]   [Full Text] [Related]  

  • 63. GLOMERULONEPHRITIS. A SURVEY OF THE FUNCTIONAL ORGANIZATION OF THE KIDNEY IN VARIOUS STAGES OF DIFFUSE GLOMERULONEPHRITIS.
    Earle DP; Taggart JV; Shannon JA
    J Clin Invest; 1944 Jan; 23(1):119-37. PubMed ID: 16695078
    [No Abstract]   [Full Text] [Related]  

  • 64. Immune Check Point Inhibitor-Associated Glomerulonephritis.
    Ashour T; Nakhoul G; Patil P; Funchain P; Herlitz L
    Kidney Int Rep; 2019 Feb; 4(2):355-359. PubMed ID: 30775635
    [No Abstract]   [Full Text] [Related]  

  • 65. Analysis of the effect of humanized nursing intervention on patients with glomerulonephritis.
    Sun W; Hao T; Cao Y
    Minerva Med; 2021 Jan; ():. PubMed ID: 33438383
    [No Abstract]   [Full Text] [Related]  

  • 66. Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting System.
    Jhaveri KD; Sakhiya V; Wanchoo R; Ross D; Fishbane S
    Kidney Int; 2016 Sep; 90(3):706-7. PubMed ID: 27521117
    [No Abstract]   [Full Text] [Related]  

  • 67. Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction.
    Krens LL; Baas JM; Verboom MC; Paintaud G; Desvignes C; Guchelaar HJ; Gelderblom H
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1303-6. PubMed ID: 24705976
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Adverse Renal Effects of Anticancer Immunotherapy: A Review.
    Borówka M; Łącki-Zynzeling S; Nicze M; Kozak S; Chudek J
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077623
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Leukocytoclastic vasculitis with purpura and renal failure induced by the anti-epidermal growth factor receptor antibody panitumumab: a case report.
    Kamo H; Shinozaki E; Sugase T; Mizunuma N; Taniguchi S; Gotoh T; Chin K; Tanaka T; Koga K; Yamaguchi K
    J Med Case Rep; 2019 Jan; 13(1):13. PubMed ID: 30646927
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review.
    Jhaveri KD; Wanchoo R; Sakhiya V; Ross DW; Fishbane S
    Kidney Int Rep; 2017 Jan; 2(1):108-123. PubMed ID: 29318210
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A SPRY2 mutation leading to MAPK/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathy.
    Milillo A; La Carpia F; Costanzi S; D'Urbano V; Martini M; Lanuti P; Vischini G; Larocca LM; Marchisio M; Miscia S; Amoroso A; Gurrieri F; Sangiorgi E
    Eur J Hum Genet; 2015 Dec; 23(12):1673-8. PubMed ID: 25782674
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Thrombotic microangiopathy associated with cetuximab, an epidermal growth factor receptor inhibitor
.
    Koizumi M; Takahashi M; Murata M; Kikuchi Y; Seta K; Yahata K
    Clin Nephrol; 2017 Jan; 87 (2017)(1):51-54. PubMed ID: 27925578
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluation of Cetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck.
    Li JZ; Zheng JW; Zhang ZY
    Shanghai Kou Qiang Yi Xue; 2008 Feb; 17(1):1-5. PubMed ID: 18360658
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cetuximab-Associated Crescentic Diffuse Proliferative Glomerulonephritis.
    Manthri S; Bandaru S; Chang A; Hudali T
    Case Rep Nephrol; 2017; 2017():7964015. PubMed ID: 29348949
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
    Eder J; Simonitsch-Klupp I; Trautinger F
    Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
    Song Q; Li X; Li B
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Diffuse proliferative glomerulonephritis associated with cetuximab, an epidermal growth factor receptor inhibitor.
    Sasaki K; Anderson E; Shankland SJ; Nicosia RF
    Am J Kidney Dis; 2013 Jun; 61(6):988-91. PubMed ID: 23474009
    [TBL] [Abstract][Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.